Slingshot members are tracking this event:

Top-Line Results on Solanezumab Phase 3 Clinical Trial in Patients with Alzheimer's Disease

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details The EXPEDITION1 study did not meet co-primary cognitive and functional endpoints in the overall mild-to-moderate patient population
Slingshot Insights Explained
Catalyst Date
Occurred on:
Apr 25, 2012
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Solanezumab, Alzheimer's